Clinical trials: TB
Tuberculosis
A Pan-TB Regimen Targeting Host and Microbe
This project will develop the first regimen meeting WHO criteria for a pan-TB indication, ie, not requiring knowledge of RIF susceptibility.
- Trial name
- panTB-HM (NCT05686356)
- Testing
- Sutezolid, N-acetyl cysteine, Pretomanid
- Where
- 8 sites in Mozambique, South Africa and 1 more
- Volunteers
- 352 people
- Sponsor
- The Aurum Institute NPC
Tuberculosis
A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential
This study is designed to assess the pharmacokinetics (PK), safety, and tolerability of Ganfeborole and Microgynon, an oral contraceptive containing ethinylestradiol (EE) and levonorgestrel (LNG), when Microgynon is administered…
- Trial name
- NCT07784894
- Testing
- Ganfeborole, Microgynon
- Where
- Spain
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Latent Tuberculosis Infection
TB mHealth Study - Use of Cell Phones to Improve Compliance in Patients on LTBI Treatment
This study will examine the impact of use of mobile phones and text messaging on adherence to treatment for patients with latent TB infection.
- Trial name
- NCT01549457
- Testing
- Cell phone text messages
- Where
- 3 sites in Canada
- Volunteers
- 350 people
- Sponsor
- University of British Columbia
Pulmonary Tuberculosis
Channa Striata and Curcuma Domestica Supplementation in Patients With Active Pulmonary Tuberculosis
This study aims to evaluate the effect of combined supplementation with Channa striata extract and Curcuma domestica rhizome on nutritional status, inflammatory markers, and quality of life in patients with active pulmonary…
- Trial name
- NCT07887724
- Testing
- CHANA STRIATA AND CURCUMA
- Where
- 2 sites in Indonesia
- Volunteers
- 80 people
- Sponsor
- DINA KEUMALA SARI
Tuberculosis
Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.
This study is designed to evaluate the safety of MVA85A in healthy volunteers in the UK who are latently infected with M.tb. A single vaccination with MVA85A, when administeredat a dose of 5 x 107pfu intradermally, is safe in…
- Trial name
- NCT00456183
- Testing
- MVA 85A
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
Assessing the Ability of the T-SPOT®.TB Test (IQ)
The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response (NTBSLR) in identifying patients with active TB disease.
- Trial name
- IQ (NCT03973970)
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Oxford Immunotec
Tuberculosis, Pulmonary
Impact of Malnutrition on Pharmacokinetic of Rifampicin, Isoniazid, Pyrazinamide and Ethambutol in TB-HIV Co-infected Children (TB-Speed TB-PK)
TB-Speed TB-PK is a cross-sectional PK study of anti-TB treatment nested in the TB-Speed HIV and TB-Speed SAM studies aiming at assessing the impact of malnutrition on PK of rifampicin, isoniazid, pyrazinamide, and ethambutol in…
- Trial name
- NCT04972903
- Where
- 4 sites in Uganda, Zambia
- Volunteers
- 85 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Post-tuberculosis Lung Disease, Tuberculosis (TB)
Pulmonary Rehabilitation Program in Patients With Post-Tuberculosis Lung Disease
Post-tuberculosis lung disease (PTLD) refers to persistent respiratory symptoms, functional limitation, and/or structural or physiological abnormalities after completion of anti-tuberculosis treatment.
- Trial name
- NCT07709507
- Testing
- Individualized Pulmonary Rehabilitation Program, Standard Post-Tuberculosis Care
- Volunteers
- 80 people
- Sponsor
- Filantropia Hospital
Tuberculosis
Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent
The purpose of this study is to evaluate safety, immunogenicity of ID93+GLA-SE compared to placebo following three intramuscular (IM) injections on Days 0, 28 and 56 in BCG-vaccinated QFT-negative healthy adolescent.
- Trial name
- NCT03806699
- Testing
- ID93+GLA-SE
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.
Tuberculosis
The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa
The purpose of this study is to compare two different methods of intensified tuberculosis (TB) case finding in the community. These methods all involve the use of a mobile clinic to reach people with TB symptoms who are not able…
- Trial name
- XACT (NCT01990274)
- Testing
- GeneXpert MTB/RIF assay, Smear microscopy
- Where
- 4 sites in Italy, Netherlands and 2 more
- Volunteers
- 875 people
- Sponsor
- University of Cape Town
Tuberculosis
A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG
A new, more specific skin test to detect tuberculosis has been developed by Statens Serum Institut in Denmark. The new skin test is named C-Tb and like the current Tuberculin a positive test result will show as redness and/or…
- Trial name
- TESEC-03 (NCT01242475)
- Testing
- C-Tb, 2 TU Tuberculin PPD RT 23 SSI
- Where
- United Kingdom
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Chronic Liver Disease, Liver Transplantation
Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing in Patients With Chronic Liver Disease
The purpose of the study is to estimate the usefulness of the QuantiFERON®-TB Gold test for the diagnosis of latent tuberculosis infection in liver transplant candidates by correlating the test results with risk factors for LTBI
- Conditions
- Chronic Liver Disease, Liver Transplantation, Tuberculosis
- Trial name
- NCT00402402
- Testing
- Tuberculin skin test, Quantiferon-TB Gold assay
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- University Health Network, Toronto
Pregnant HIV Positive Women, HIV
TB SCReening Improves Preventive Therapy Uptake in Pregnant Women With HIV
Because pregnant women have been excluded from clinical research, including tuberculosis (TB) research, little is known about diagnosing, treating and preventing TB in pregnant women.
- Conditions
- Pregnant HIV Positive Women, HIV, Tuberculosis (TB)
- Trial name
- TB SCRIPT-Moms (NCT07278453)
- Testing
- CRP screening (TB screening intervention arm), Deferred TPT (TPT delivery trial intervention arm)
- Where
- Uganda
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Active Tuberculosis
Serological Test for the Diagnosis of TB
TB remains a health problem in France with about 5,000 new cases per year. Development of new screening tests is a priority for TB.
- Trial name
- MycoTB (NCT02898623)
- Testing
- No intervention
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Montpellier
Tuberculosis
A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A
The purpose of this study is to evaluate the BCG 'challenge' model a four-arm study design has been chosen. Twelve subjects will be recruited into each arm of the study.
- Trial name
- NCT01194180
- Testing
- BCG: 100 microlitres ~ 2-8 x 105 pfu, MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
PK Study of Anti-TB Drugs
This is a prospective descriptive and pharmacokinetic study will be conducted among newly diagnosed patients registered in the two SMRU TB clinics located on the Thai-Myanmar border.
- Trial name
- NCT02457208
- Testing
- Isoniazid (H), Rifampicin (R), Pyrazinamide (Z)
- Where
- Thailand
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Oxford
HIV, Tuberculosis
TasP in Correctional Facilities
At correctional facilities in Zambia and South Africa, a cross-sectional study design will be used to characterize the full continuum of integrated HIV/TB care under Treatment as Prevention (TasP), and will enrich this approach…
- Trial name
- NCT02946762
- Testing
- Test and treat
- Where
- Zambia
- Volunteers
- 419 people
- Sponsor
- University of North Carolina, Chapel Hill
Tuberculosis, Multidrug-Resistant
Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis
Acquired drug-resistance is a major challenge for tuberculosis (TB) care programs. The 2020 WHO guidelines recommends replacing second-line injectables by bedaquiline in rifampicin-resistant TB (RR-TB) treatment regimens.
- Trial name
- Stake (NCT05555303)
- Testing
- Amikacin
- Where
- Rwanda
- Volunteers
- 20 people
- Sponsor
- Rwanda Biomedical Centre
Tuberculosis
Evaluation of the QuantiFERON-TB Test.
To compare the results of the investigational test to the currently approved QuantiFERON-TB Gold In-Tube test.
- Trial name
- NCT02142894
- Testing
- CST001
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Tuberculosis, HIV
Alcohol Reduction Among People With TB and HIV in India
The highest incidence of tuberculosis disease (TB) in the world is in India, accounting for 27% of all new cases globally, with approximately 86,000 among persons with HIV (PWH).
- Trial name
- HATHI (NCT04230395)
- Testing
- HATHI Intervention, Usual Care
- Where
- 2 sites in India
- Volunteers
- 450 people
- Sponsor
- Johns Hopkins University